Epidemiological Insights and Duffy Binding Protein Evolution of *Plasmodium vivax* in Duffy-Negative Cameroonians

Authors: Cheikh Cambel Dieng[1]*, Rene Teh Ning[2], Canelle Kipayko[1], Regan Schroeder[1], Nontokozo Mdluli-Berndt[1], Bate Ayukenchengamba[2], Zidedine Nematchoua[2], Sona Doris[2], Ambendekson Elizabeth Reward[2], Irene Sumbele Ngole Ule[2], Helen Kuokuo Kimbi[2,3], Eugenia Lo[1]*

Affiliations:

[1]Department of Microbiology and Immunology, College of Medicine, Drexel University Philadelphia, Pennsylvania, USA

[2]Department of Animal Biology and Conservation (ABC), Faculty of Science, University of Buea, Buea, Cameroon

[3]Department of Biomedical Sciences, University of Bamenda, Bamenda, Bambili, Cameroon

***Address for correspondence**: Cheikh Cambel Dieng, Department of Microbiology and Immunology, College of Medicine, Drexel University, Philadelphia 19129, Pennsylvania, USA; email: cd3424@drexel.edu; Eugenia Lo, email: el855@drexel.edu

Short running title: *P. vivax* in Duffy negative Cameroonians

Abstract

Malaria remains a major public health concern in sub-Saharan Africa, and *P. vivax* is emerging in regions with predominantly Duffy-negative populations. This study investigated *P. vivax* prevalence and genetic diversity across three ecological zones in Cameroon. *P. vivax* was detected in ~11% of febrile patients and 5.5% of asymptomatic individuals, all are Duffy-negatives. Clinical infections exhibited higher parasitemia than infections detected in the communities. Standard PvLDH-based RDTs produced false-negative results, even at high parasitemia levels, whereas molecular tools like qPCR demonstrated superior sensitivity. Genetic analysis of *PvDBP1* identified two prevalent mutations, I379L (73%) and E225K (61%), among samples, suggesting adaptive evolution. Phylogenetic analysis clustered Cameroonian isolates with those from Botswana but distinct from the Ethiopian and Sudanese isolates, indicating historical migration and local adaptation. The detection of asymptomatic *P. vivax* cases highlights the potential for transmission, reinforcing the need for enhanced surveillance in both community and clinical settings.

Keywords: Malaria; *Plasmodium vivax*; *Plasmodium falciparum,* Duffy binding protein*,* febrile patients, asymptomatic infections*,* Cameroon

42 **Introduction**

43 Malaria remains a significant global health challenge in sub-Saharan Africa. For decades,
44 *Plasmodium vivax* (*Pv)* was thought to be rare in African populations that lack the Duffy blood
45 group antigen expression. However, emerging evidence has identified *Pv* cases in Duffy-
46 negative individuals across Africa, challenging this conventional dogma. The endemic range of
47 *Pv* has extended beyond the Horn of Africa and penetrated Duffy-negative regions (>95%). A
48 point mutation (c.1–67T>C; rs2814778) in the GATA-1 transcription factor binding site of the
49 Duffy antigen/receptor for chemokines (DARC) gene promoter alters erythroid expression,
50 reducing Duffy antigen expression on the surface of the red blood cells (1, 2).

51 In sub-Saharan Africa, malaria prevalence varies significantly by region and season. For
52 instance, in Cameroon, the highest prevalence occurs in the western and northern regions that are
53 mostly highlands, which could exhibit different malaria transmission dynamics compared to the
54 lowlands in the eastern region (3). Malaria prevalence also varies significantly by season,
55 ranging from 30% in the dry season from November to February to 65% during the rainy season
56 from March to October. The western part of Cameroon experiences heavy seasonal rainfall,
57 which drives malaria transmission. While *P. falciparum* (*Pf*) remains the dominant parasite
58 species, *Pv* cases have been reported among travelers who acquired infections in Cameroon and
59 were diagnosed after returning to their home countries (4, 5). "*Pv*-like" asymptomatic infections
60 have also been detected by microscopy in schoolchildren in the Mount Cameroon area. Two
61 recent studies also reported an infection rate of 5.6% (6) and 35% (7) of *Pv* in febrile Duffy-
62 negative individuals in Dschang, northwestern Cameroon by PCR. However, most of these
63 studies were case reports and did not assess the broader epidemiological or genetic

characteristics of *Pv* in the region. The extent of genetic polymorphisms of the Duffy Binding Protein (DBP) gene, a key gene that the parasites use to invade human erythrocytes via DARC (8), is unclear among *Pv* from Duffy-negative populations in Central Africa. Such variations may influence the adaptability and geographic spread of *Pv* across Africa.

Environmental factors such as temperature, rainfall, and elevation can shape *Pv* transmission dynamics through their effects on mosquito vectors and parasite development. Across Cameroon's diverse ecological zones, these conditions may influence regional patterns of *Pv* transmission (9). In this study, we assessed *Pv* prevalence among the northwest, southwest, and eastern regions of Cameroon in both community and hospital settings. We further examined *Pv* genetic polymorphisms from these regions and compared them to isolates from East Africa and beyond, to evaluate genetic diversity and infer evolutionary relationships. Understanding the epidemiological and genetic features of *Pv*, particularly in Duffy-negative populations, is essential for informing malaria surveillance and control strategies in Africa.

Methods

Ethical Statement

The study protocol was approved by the Institutional Review Boards of the Universities of Buea and Bamenda (Ref No. 2024/2110-06/UB/SG/IRB/FHS). Informed consent was obtained from all participants or their legal guardians. All methods were carried out in accordance with relevant guidelines and regulations.

85 **Study Sites and Sample Collection**

86 A cross-sectional study was conducted across three study sites in Cameroon including Bamenda,
87 Buea, and Bertoua. Site selection was based on variation in climate and landscape. Bamenda lies
88 in a highland region (1201–1400 m). Buea, at 530 meters elevation, is a multi-ethnic semi-urban
89 area with year-round malaria transmission (10, 11). Bertoua, in the Eastern region, has a wet
90 equatorial climate and is known for timber and mining industries (9). A total of 1,373 samples
91 (408 samples from Buea, 498 from Bamenda, and 467 from Bertoua) were collected between
92 April and August 2023, of which 793 were from febrile patients at health facilities and 580 from
93 community households. Among all samples, 555 were males and 818 were females. For each
94 individual, 30–50 µL of finger-pricked blood was spotted onto Whatman 3MM filter paper, air-
95 dried, and stored until DNA extraction. Thick and thin blood smears were also prepared for
96 microscopic screening of *Plasmodium*.

97

98 ***Plasmodium* Screening, Duffy Genotyping, and *PvDBP1* Sequencing**

99 *Plasmodium* species were initially determined using rapid diagnostic tests (RDTs; Bioline
100 Malaria Ag Pf/Pv manufactured by Abbott Inc) specific to *Pf* (PfHRP2) and *Pv* (PvLDH), as
101 well as microscopy. Molecular assays were conducted for further diagnosis. Parasitic DNA was
102 extracted from dried blood spots using a modified Chelex®-saponin method (12, 13).
103 Quantitative PCR (qPCR) targeting the 18S rRNA gene was used to identify mono-*Pv* and mixed
104 *Pv*-*Pf* infections (14). Parasitemia was measured via SYBR Green detection method, using *Pv*-
105 specific primers (S1Table) (13). Each run included positive controls from *Pv* Pakchong (MRA-

342G) and Nicaragua (MRA-340G) isolates, along with negative controls. A standard curve was generated based on a ten-fold serial dilution of a *Pv* control plasmid to assess amplification efficiency (E). Specificity of the amplification was verified by melting curve analysis. For each sample, the mean cycle threshold (Ct) value and standard error were calculated from three independent runs. Parasitemia was determined using the equation: $2^{E} \times (40 - Ct_{sample})$.

For each sample, *PvDBP1* region II was also amplified using published primers (forward: 5′-GATATTGATCATAAGAAAACGATCTCTAGT-3′; reverse: 5′-TGTCACAACTTCCTGAGTATTTTTTTTAGCCTC-3′) (15), designed based on the *P. vivax* reference sequence PVX_110810 from the Sal I strain (NC_009911.1). The amplification was performed following the published protocol (15). PCR products were purified prior to Sanger sequencing. For host Duffy genotyping, a TaqMan qPCR assay was used to examine the point mutation (c.1–67T>C; rs2814778) of the *DARC* gene (16) . A no-template control was used in each assay. Genotypes were determined by the allelic discrimination plot. In addition, a 1,100-bp fragment of the *DARC* gene was further amplified for a subset of samples using published primers for Sanger sequencing to confirm Duffy genotypes (17).

Data analysis

To evaluate factors associated with mono-*Pv* and mixed *Pv*-*Pf* infections, odds ratios (OR) and 95% confidence intervals (CI) were calculated for various demographic, clinical, and epidemiological variables. Demographic variables including gender (male vs. female), age (<5 years, 5–15 years, and >15 years), and collection origin (community vs. hospital-based) were

127 analyzed to examine the potential risk factors for infection. Symptom-based analyses were
128 conducted to assess differences in clinical presentation across infection types. MedCalc software
129 was used for all statistical analysis.

130 *PvDBP1* sequences were aligned to the P01 (PlasmoDB-67_PVP01) reference strain
131 using MUSCLE in Geneious vX.1. Codon mutations in the Cameroonian *Pv* were compared with
132 isolates from Thailand and China (Asia), Brazil (South America), Sudan and Ethiopia (East
133 Africa), and Botswana (Southern Africa) that represent geographically and epidemiologically
134 diverse regions. Phylogenetic trees were constructed using Maximum Likelihood (ML) method
135 in RAxML. The ML tree was generated with 1,000 bootstrap replicates. The General Time
136 Reversible (GTR) model with gamma distribution was used to account for rate heterogeneity.
137 The resulting tree was imported into FigTree v1.4.4 for visualization. Sequences are available
138 under GenBank submission number 2920113.

139

140 **Results**

141 **Prevalence of *Pv* infections among Duffy-negatives**

142 The prevalence of mono-*Pv* and mixed *Pv*-*Pf* infections varied significantly across study sites
143 (Figure 1). Among 793 hospital samples, mono-*Pv* prevalence was 11% (n=86), mono-*Pf* was
144 24.5% (n=192), and mixed *Pv*-*Pf* infections were 13.5% (n=106; Figure 2A, Table 1). All *Pv*
145 infections were Duffy-negative (CC) per TaqMan genotyping. The highest rates of mono-*Pv* and
146 mixed *Pv*-*Pf* infections were found in females over 15 years old in Bamenda (6% and 3.8%).

147 Among 580 community samples, mono-*Pv* prevalence was 5.5% (n=32), mono-*Pf* was 39.5%
148 (n=229), and mixed *Pv*-*Pf* infections were 7.2% (n=42). *Pv* infection rates were comparable
149 between females (8.9%) and males (8.1%, OR=1.11, p=0.597). Similarly, mixed infections
150 occurred in 11.1% of females and 10.3% of males (OR=1.09, p=0.617). No significant
151 differences in parasitemia were observed between mono- and mixed infections, sexes, or age
152 groups (Figure 2B; S1 Fig.; S2 Fig.).

153 Of 119 *Pv*-positive samples by 18S-qPCR, 112 (94%) were confirmed by *PvDBP*1-based
154 PCR. However, all qPCR-positive samples were microscopy-negative, and only 15 (12.6%) were
155 RDT-positive (Table 2). These 15 RDT-positive samples showed relatively low Ct values (i.e.,
156 high parasite DNA copies) by qPCR (Table 2). These findings highlighted the limited sensitivity
157 of conventional diagnostics in detecting *P. vivax* infections, particularly in Duffy-negative
158 individuals. While clinical samples had significantly higher average parasitemia than community
159 samples (p<0.001; Figure 3), several community-based (asymptomatic at the time of collection)
160 infections were shown with relatively high parasitemia. Specifically, 13% of community samples
161 had parasitemia >1,000 parasites/μL, compared to 21% of hospital cases showing such level of
162 parasitemia.

163

164 **Association Between Age, Infection Type, and Symptoms**

165 Age-stratified analysis revealed significant trends in malaria prevalence. Individuals aged 5–15
166 years had a significantly lower risk of *Pv* infection compared to children under 5 years
167 (OR=0.67, p=0.01). It is not surprising that *Pv* was more common in hospital-based participants

168 (10.8%) than those from the community (5.5%), though this difference was not statistically
169 significant (OR=1.16, p=0.162). Likewise, mixed infections were also more common in hospital
170 (13.3%) than community samples (7.2%), with a significant two-fold increased risk (OR=2.04,
171 p<0.001). Mono-Pv infections were not associated with specific symptoms, while headache was
172 significantly associated with *Pf* infections (OR=3.33, p=0.004; Table 3).

173

174 **Genetic polymorphisms of *PvDBP1* and Phylogenic Relatedness**

175 Eight mutations were identified in the *PvDBP1* region II (amino acid 291-460) among 75 *P.*
176 *vivax* isolates from Cameroon. Two of the mutations occurred at high frequency in the Duffy-
177 negative populations, including I379L observed in 74.1% and E225K in 53.7% of the samples
178 (Figure 4A). Other less frequent mutations included N372K (27.8%), G339D (22.2%), W442C
179 (11.1%), K234E (47.1%), K326E (7.4%), and G417V (5.6%). Variants K326E, G339D, N372K,
180 and I379L were shared with the Thai isolates, though I379L (30%) and G339D (19%) were
181 observed at considerably lower frequencies in Thailand (Figure 4B). Only K326E and N372K
182 were shared between the Cameroonian and Botswana isolates. The Chinese *Pv* were the most
183 polymorphic with 13 variants detected in the binding region, four of which (L333F, N375D,
184 S398T, and T404R) were unique and not observed elsewhere. The remaining nine variants were
185 overlapped with the Sudanese, Ethiopian, and Brazilian isolates. However, none of these variants
186 were detected in the Cameroonian or Botswana *Pv*. The Cameroonian *Pv* shared only N417K
187 with the Brazilian/East African isolates (Figure 4B).

188 Phylogenetic analysis revealed distinct clustering of *Pv* isolates by geographic region
189 (Figure 5A), with East African and Asian *Pv* showing high genetic relatedness, and South
190 American *Pv* forming a separate clade distinct from the other regions. Within Africa (Figure 5B),
191 most of the isolates from Cameroon (red) form a distinct cluster, sister to those from Botswana
192 (light blue). Two other main clades were observed—one contained most of the Ethiopian
193 (purple) and Ugandan (orange) isolates, and another contained the Ethiopian and Sudanese
194 (green) isolates—indicating the genetic diversity among the African *P. vivax*.

195

196 **Discussion**

197 Molecular assays targeting 18S rRNA and *PvDBP1* revealed a substantial number of *Pv*
198 infections across Cameroon. These findings challenge the longstanding dogma that Duffy-
199 negative individuals are resistant to *Pv*, suggesting instead that the parasite may have well-
200 adapted and circulating widely in Central Africa (7, 16, 18). Geographic and environmental
201 factors strongly influence *Pv* transmission dynamics (19). The southwest region of Cameroon,
202 like Buea at high altitude on Mount Cameroon, provides favorable conditions such as cooler
203 temperatures for the development of *Pv*. Unlike *Pf*, which requires warmer temperatures (18°C
204 and above) mosquito-stage development, *Pv* can survive at 16–18°C, enabling it to transmit in
205 cooler regions (20). High rainfall and flooding in Buea and Bamenda may enhance transmission
206 compared to Bertoua (21). Recent studies suggest that malaria is expanding its endemic range to
207 higher altitudes, including regions such as the Ethiopian highlands (18), Kenya (19), and
208 Colombia (21). In Ethiopia, *P. vivax* has spread into previously malaria-free highland areas with
209 a mono-*P. vivax* infection rate of ~8%, similar to our findings in this study. It is apparent that

210 *vivax* malaria will increasingly burden the densely populated highlands of Africa and South
211 America. Due to socio-political unrest and large-scale migration in the English-speaking regions
212 of Cameroon since 2016, *Pv* may have readily spread to different parts of Cameroon or beyond.
213 The prevalence of *Pv* infection varied notably by age group. Individuals aged 5–15 years had a
214 significantly lower risk than children under 5 years, suggesting partial immunity or reduced
215 exposure (22). The potential spread and adaptation of *P. vivax* emphasizes the need to consider
216 geographical and environmental heterogeneity when developing malaria control and intervention
217 strategies.

218 While hospital-based cases had higher parasitemia, some asymptomatic community
219 infections were also shown with high parasitemia, indicating transmission potential. In Ethiopia,
220 *Pv* in Duffy-negative individuals was observed in both febrile patients and asymptomatic carriers
221 (23, 24), and some of these infections were detected with gametocytes (25). These findings
222 emphasize the need for comprehensive surveillance and interventions in both hospital and
223 community settings. The use of microscopy and RDT diagnostics, though convenient, could have
224 vastly misidentified or missed low-density *P. vivax* infections. In our study, some individuals
225 classified as microscopy-negative showed moderate to high parasitemia by qPCR, raising
226 concerns about the diagnostic sensitivity of microscopy and PvLDH-based RDTs, especially in
227 Duffy-negative individuals. Similar microscopy results have been reported in a study from
228 Indonesia(26), where microscopy detected only 5 mixed infections of *P. falciparum* and *P. vivax*,
229 while nested PCR detected 346 cases across various clinical categories, including asymptomatic
230 individuals and those recently treated with antimalarials. Notably, all microscopy results were
231 negative in individuals' post-treatment, while PCR still detected ongoing parasitemia in most
232 cases(26). Additionally, our findings also suggest that PvLDH-based RDTs may contribute to

233 false-negative results, even in cases of high parasitemia. This could be attributed to defective or
234 degraded test kits, lot variability, or antigenic variation that affects the detection capability of
235 PvLDH in majority Duffy-negative Africa. Molecular tools like qPCR offer superior sensitivity
236 and specificity, particularly in detecting low-density or mixed *P. vivax* infections in Duffy-
237 negative individuals, ensuring both symptomatic and asymptomatic carriers are identified and
238 monitored effectively.

239 The *PvDBP1* gene encodes a critical ligand that facilitates *P. vivax* invasion of
240 human erythrocytes by binding to the Duffy antigen receptor, making it a key molecular marker
241 for both species confirmation and evolutionary analysis. While previous studies in Cameroon
242 have documented the presence of *P. vivax*, this is the first study to utilize *PvDBP1* not only to
243 validate *P. vivax* infections in Duffy-negative individuals, but also to examine genetic variations
244 and phylogenetic relationships of the Cameroonian isolates with global *P. vivax* populations**.** In
245 the Cameroonian isolates, mutations I379L and E225K occurred at notably high frequencies.
246 These and several other identified mutations, including K326E, G339D, and N372K overlapped
247 with *P. vivax* populations from Southeast Asia(27). Mutations I379L and G339D occurred at
248 substantially higher frequencies in our dataset than other geographical isolates, suggesting
249 regional adaptation or selective pressures in Central African parasite populations. These findings
250 highlight the need for future functional assays to clarify their potential role in parasite invasion
251 and virulence.

252 Previous studies indicated striking similarity of the *Pv* genome between Asian and East
253 African parasite populations with high identity-by-descent (20). Our prior research showed no
254 clear genetic distinction between *Pv* in Duffy-negative and Duffy-positive hosts, indicating

255 shared ancestry and gene flow (16, 28). This study further shows that Cameroonian and
256 Botswanan *Pv* form a distinct cluster, separate from East African isolates, likely due to
257 ecological adaptation and vector diversity. For instance, *Pv* parasites show strong compatibility
258 with local mosquito vectors (29). In Cameroon and Benin, *Anopheles coluzzii* was identified as a
259 competent vector for *Pv* (30), suggesting its potential significance in sustaining transmission in
260 West/Central Africa (31). By contrast, in East Africa, *An. arabiensis* and *An. funestus* are
261 primary vectors for malaria transmission. While *An. arabiensis* is more commonly associated
262 with *Pf*, there is evidence suggesting its potential role in transmitting *Pv* (32-34). Such vector
263 differences may drive *Pv* population divergence between regions.

264 Apart from vector-parasite co-evolution, host genetic factors may also shape parasite
265 population structure. Evidence of severe population bottlenecks followed by rapid expansion in
266 human *Pv*, along with gene pseudogenization (e.g., RBP2d, RBP3) supports host-specific
267 adaptation in *Pv* (35). East Africa, with a larger Duffy-positive population, likely harbors an
268 older, more diverse *Pv* gene pool; whereas Central/Southern Africa may represent a portion of
269 *Pv* parasites recently introduced from East Africa or constrained populations shaped by
270 bottlenecks and the predominance of Duffy-negative hosts (35, 36). The observed genetic
271 relatedness between Cameroonian and Botswanan isolates suggests possible recent gene flow.
272 The Bantu expansion is the most significant and well-studied migration event between Central
273 and Southern Africa, where Bantu-speaking people migrated from West-Central Africa,
274 eventually settling in much of the southern half of the continent and interacting with indigenous
275 groups like the Khoisan, around 3,000 to 5,000 years ago (37, 38). This migration event could
276 have shaped the parasite population structure.

This study has a few limitations. First, samples and related metadata were collected at a single timepoint and thus restricts our ability to assess *Pv* transmission over time. Also, the genetic analysis based on *PvDBP1* alone does not reflect evolutionary changes at the genome level for *Pv* in Duffy-negative individuals. The geographic representation of African *Pv* isolates, particularly samples from West Africa, is limited in the phylogenetic analysis. The apparent genetic distinctiveness of Central African isolates may change with broader sampling across the continent. Our ongoing investigations use a genome-based approach together with spatial analyses to determine source-sink dynamics of *Pv* infections, with the goal to unravel the origin and adaptation of *Pv* in Africa.

To conclude, the detection of several *Pv* cases in asymptomatic individuals underscores its potential for silent transmission, emphasizing the need for enhanced surveillance in both community and clinical settings. PvLDH-based RDTs may contribute to false-negative diagnostic results, even in cases of high parasitemia. Molecular tools like qPCR offer superior sensitivity and specificity, particularly in detecting low-density or mixed *Pv* in Duffy-negative individuals. Our present findings call for tailored malaria control strategies that consider both geographical/environmental heterogeneity and the unique features of *Pv* in Duffy-negative populations.

Acknowledgments

We thank the dedicated field team in Cameroon for their invaluable efforts in sample collection, processing, and logistical support; the communities and hospitals for their support and willingness to participate in this research; and our collaborators and supporting institutions for their contributions and insights, which have significantly enriched this research.

Funding

This research was supported by NIH/NIAID R21AI190606. The funding body had no role in the study design, data collection, analysis, manuscript preparation, or decision to publish.

Disclosure of Interest

The authors declare no conflict of interest.

Table 1. Prevalence of Mono-*Plasmodium vivax*, Mono-*Plasmodium falciparum*, and mixed infections across different sex and age groups in Bamenda, Bertoua and Buea. This table summarizes the infection prevalence of Mono-*Plasmodium vivax* (Mono-Pv), Mono-*Plasmodium falciparum* (Mono-Pf), and Mixed Infections across three sites in Cameroon (Bamenda, Bertoua, and Buea). Data are stratified by sex and age groups (>15 years, <5 years, 5-15 years). For each site, the total number of cases and the percentage distribution of infections are provided. Chi-square tests were conducted to assess the association between infection type (Mono-Pv, Mono-Pf, Mixed) and demographic variables (age group, sex). Significant differences were observed in infection prevalence among different age groups, with higher mixed infection rates observed in females, especially children under 5, indicating a greater vulnerability to mixed infections (p-value < 0.05). Specifically, the highest prevalence of mixed infections was observed in Bamenda (36.54%), followed by Bertoua (34.26%) and Buea (29.20%).

Origin	Site	Sex	Age	Mono-*P.v*	Mono-*P.f*	Mixed Infection	*P.v*, *P.f* negative	Total
Hospital	Bamenda	Female	>15	6.0% (30)	3.2% (16)	3.8% (19)	27.3% (136)	40.4% (201)
			<5	1.4% (7)	4.4% (22)	3.8% (19)	9.8% (49)	19.5% (97)
			5-15	0.4% (2)	1.0% (5)	0	1.0% (5)	2.4% (12)
		Male	>15	1.2% (6)	1.2% (6)	0.6% (3)	8.6% (43)	11.7% (58)
			<5	1.6% (8)	3.4% (17)	2.4% (12)	16.1% (80)	23.5% (117)
			5-15	0.2% (1)	0	0.2% (1)	2.2% (11)	2.6% (13)
	Buea	Female	>15	5.6% (16)	18.2% (52)	6.7% (19)	15.1% (43)	45.6% (130)
			<5	0.7% (2)	5.6% (16)	1.1% (3)	2.8% (8)	6.7% (29)
			5-15	0.4% (1)	2.8% (8)	2.5% (7)	2.8% (8)	8.5% (24)
		Male	>15	2.8% (8)	7.7% (22)	4.2% (12)	4.2% (12)	18.9% (54)
			<5	1.1% (3)	5.6% (16)	1.8% (5)	2.8% (8)	11.2% (32)
			5-15	0.7% (2)	4.2% (12)	2.1% (6)	2.1% (6)	9.1% (26)

	Total (%)			10.9% (86)	24.5% (192)	13.5% (106)	52.2% (409)	100% (793)
Community	**Bertoua**	**Female**	**>15**	0.6% (3)	7.5% (35)	1.9% (9)	11.3% (53)	21.4% (100)
			<5	0.2% (1)	5.1% (24)	0.2% (2)	6.4% (30)	12.2% (57)
			5-15	0.9% (4)	11.3% (53)	0.21% (6)	7.9% (37)	21.4% (100)
		Male	**>15**	0.2% (1)	3.4% (16)	0.6% (3)	4.3% (20)	8.6% (40)
			<5	0.4% (2)	7.1% (33)	0.9% (4)	5.1% (24)	13.5% (63)
			5-15	0.21% (6)	9.9% (46)	1.7% (8)	10.1% (47)	22.9% (107)
	Buea	**Female**	**>15**	6.2% (7)	8.8% (10)	6.2% (7)	38.9% (44)	60.2% (68)
			<5	0	0	0	0	0
			5-15	0	0	0	0	0
		Male	**>15**	6.2% (7)	10.6% (12)	2.7% (3)	19.5% (22)	38.9% (44)
			<5	0.9% (1)	0	0	0	0.9% (1)
			5-15	0	0	0	0	0
	Total (%)			5.5% (32)	39.5% (229)	7.2% (42)	47.8% (277)	100% (580)

Table 2. Detection of *Plasmodium vivax* Infections across Hospital- and Community-Based Samples. This table shows the *P. vivax* detection using 18S-qPCR, *PvDBP1*-targeted PCR (DBP-PCR), microscopy, and rapid diagnostic tests (RDTs) in hospital-based (N = 793) and community-based (N = 580) samples. Most infections, particularly those with higher Ct values (indicative of lower parasite densities), were undetectable by microscopy and RDT. All qPCR-positive *P. vivax* samples were from Duffy-negative individuals.

Ct range by qPCR	18S-qPCR	DBP-PCR+	Microscopic+	RDT+
Hospital-based samples (total *N*= 793)				
<20	0	0	0	0
20 - <25	5	5	0	5
25 - <30	17	17	0	7
30 - <35	20	18	0	0
>35 - <38	45	43	0	0
Community-based samples (total *N*= 580)				
<20	3	3	0	3
20 - <25	3	2	0	0
25 - <30	1	1	0	0
30 - <35	4	4	0	0
>35 - <38	21	19	0	0

Table 3. Demographic, Geographic, and Symptom-Based Risk Factors Associated with *Plasmodium vivax*, *Plasmodium falciparum*, and Mixed Infections. This table presents the distribution of malaria infections across various demographic, geographic, and clinical symptom categories. Significant associations ($p<0.05$) were observed for several risk factors. Individuals aged 5–15 years had a significantly lower risk of *P. vivax* infection, while those older than 15 years had a higher risk of *P. falciparum* infection. Hospital-based samples had a higher prevalence of mixed infections, and a lower prevalence of *P. falciparum* compared to community-based cases. Among clinical symptoms, headache was significantly associated with *P. falciparum* infection, whereas no other symptoms showed strong associations. These findings suggest that age, geographic origin, and specific clinical presentations contribute to malaria transmission dynamics and severity.

Variables	Number of Samples	Total Infections	Odds ratio [95% CI]	*P. vivax*	Odds ratio [95% CI]	*P. falciparum*	Odds ratio [95% CI]	Mixed Infections	Odds ratio [95% CI]
Overall									
	1373	50.0% [687]		8.6% [118]		30.7% [421]		10.8% [148]	
Sex									
Female	59.5% [818]	58.9% [405]	1	8.9% [73]	1	29.5% [241]	1	11.1% [91]	1
Male	40.4% [555]	41.0% [282]	0.95 [0.77 to 1.18] **P= 0.636**	8.1% [45]	1.11 [0.75 to 1.64] **P= 0.597**	32.4% [180]	0.87 [0.69 to 1.09] **P= 0.242**	10.3% [57]	1.09 [0.77 to 1.55] **P= 0.617**
Age									
<5	28.8% [396]	28.5% [196]	1	5.9% [23]	1	33.2% [128]	1	11.7% [45]	1
5-15	20.5% [282]	24.6% [168]	0.67 [0.49 to 0.91] **P= 0.01***	5.7% [16]	1.03 [0.53 to 1.98] **P= 0.941**	43.9% [124]	0.61 [0.44 to 0.83] **P= 0.002****	9.9% [28]	1.16 [0.71 to 1.91] **P= 0.553**
>15	50.6% [695]	46.9% [322]	1.14 [0.89 to 1.53] **P= 0.314**	11.2% [78]	0.49 [0.30 to 0.79] **P= 0.004****	24.3% [169]	1.49 [1.13 to 1.95] **P= 0.004****	10.8% [75]	1.06 [0.72 to 1.57] **P= 0.772**

Origin									
Community	42.2% [580]	52.2% [303]	1	5.5% [32]	1	39.5% [229]	1	7.2% [42]	1
Hospital	57.7% [793]	48.4% [384]	1.16 [0.94 to 1.44] **P= 0.162**	10.8% [86]	0.48 [0.32 to 0.73] **P= 0.001****	24.2% [192]	2.04 [1.62 to 2.58] **P < 0.0001****	13.3% [106]	0.51 [0.35 to 0.74] **P= 0.0004****
Symptoms									
Fever	0.3% [4]	0.29% [2]	1	25.0% [1]	1	25.0% [1]	1	0	1
Chills	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P = 0.378**
Abdominal Pain	0.4% [5]	0.29% [2]	1.50 [0.11 to 21.31] **P = 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0	4.71 [0.15 to 151.49] **P= 0.381**	40.0% [2]	0.15 [0.01to 4.39] **P= 0.275**
Headache* (data missing)	0.8% [11]	0.73% [5]	1.20 [0.12 to 11.87] **P= 0.876**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	27.3% [3]	0.27 [0.01 to 6.46] **P= 0.419**
Nausea	0.1% [1]	0	3.00 [0.08 to 115.35] **P= 0.555**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	0.33 [0.00 to 25.41] **P= 0.619**
Diarrhea	0.2% [2]	0	5.00 [0.15 to 166.59] **P= 0.368**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	0.56 [0.01 to 37.56] **P= 0.785**
Difficulty Breathing	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P= 0.378**
Muscle Pain	0.4% [5]	0.44% [3]	0.67 [0.05 to 9.47] **P= 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0.20% [1]	1.33 [0.06 to 31.12] **P= 0.858**	40.0% [2]	0.16 [0.00 to 4.39] **P= 0.275**

Fatigue	0.7% [9]	0.44% [3]	2.00 [0.18 to 22.05] **P= 0.571**	22.2% [2]	0.67 [0.05 to 9.47] **P= 0.765**	0	8.14 [0.26 to 250.74] **P= 0.230**	11.1% [1]	0.63 [0.02 to 18.83] **P= 0.789**

381 **Figure 1. Study sites across Cameroon (Bamenda, Buea, and Bertoua) by hospital and**
382 **community-based collection and infection type including mono-*P. vivax*, mono-*P.***
383 ***falciparum*, mixed *P. vivax* and *P. falciparum*, and negative samples.** The prevalence of
384 mono-*P. vivax* and mixed *P. vivax*-*P. falciparum* infections showed significant variation across
385 the study sites.

386

387 **Figure 2. Comparison of *Plasmodium vivax (Pv)* and *Plasmodium falciparum (Pf)* Infections**
388 **Across Hospital and Community Settings and Parasitemia Levels in Mono and Mixed**
389 **Infections**. (**A**) Panel shows the number of cases for *P. vivax* and mixed *P. vivax* and *P.*
390 *falciparum* infections across hospital (orange bars) and community (olive green bars) settings.
391 Among the hospital samples, 10% (86) were positive for *P. vivax* while 52.3% (409) samples
392 showed mixed infections, with both *P. vivax* and *P. falciparum* present. In community samples,
393 5.5% (32) were positive for *P. vivax* and 47.8% (277) samples showed mixed infections**.**

394

395 **Figure 3. Comparative Analysis of Parasitemia Levels by Sample Origin in *P. vivax***
396 **Infections.** Compares parasitemia levels between hospital and community samples, showing
397 significantly higher parasitemia in hospital samples.

398

399 **Figure 4**. **Distribution of DBP Gene Mutations in *P. vivax* Isolates from Cameroon and**
400 **Global Comparisons:** (**A**) The bar chart illustrates the frequency of *Plasmodium vivax* Duffy
401 Binding Protein (DBP) gene mutations in isolates from Cameroon. The mutations E225K,

402 K234E, K326E, G339D, N372K, I379L, G417V, and W442C were observed with varying
403 prevalence, with I379L showing the highest frequency. Mutations marked with an asterisk (*)—
404 K326E, G339D, N372K, and I379L—are also observed in Thailand. (**B**) Comparison of *PvDBP1*
405 Region II mutations observed in *P. vivax* isolates from Cameroon with those reported in
406 geographically and epidemiologically diverse regions, including Thailand and China (Asia),
407 Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa).
408 Cameroon shared four mutations (K326E, G339D, N372K, and I379L) with Thailand, though the
409 frequencies of I379L and G339D were lower in Thai isolates. K326E and I379L were also found
410 in Botswana. Brazilian and Sudanese/Ethiopian isolates exhibited a broader mutation profile,
411 including several variants not found in Cameroon. Chinese isolates displayed unique mutations
412 such as L333F, S398T, and T404R.

413

414 **Figure 5. Global and Regional Phylogenetic Relationships of *Plasmodium vivax* Isolates.**
415 This figure illustrates the phylogenetic relationships of *Plasmodium vivax* isolates from different
416 geographical regions using whole genome sequence data: (**A**) Displays a circular phylogenetic
417 tree that segregates *P. vivax* populations into major global regions, including Central-South
418 Africa, South America, Asia, and East Africa; (**B**) Presents a radial phylogenetic tree, with color-
419 coded branches corresponding to isolates from Cameroon (red), Botswana (light blue), Uganda
420 (orange), Ethiopia (purple), Sudan (green), and reference genomes (yellow). Both trees
421 demonstrate the genetic diversity and evolutionary divergence of *P. vivax* across different
422 geographical populations, with significant clustering observed among isolates from specific
423 regions. The phylogenetic structure highlights potential gene flow and regional adaptation

424 patterns, particularly in East African populations. These insights are crucial for understanding the

425 evolutionary history and transmission dynamics of *P. vivax* on both global and regional scales.

426

427 **References**

428 1. Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB, Amoah LE, Afrane YA, et al.
429 Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in
430 Ghana: Implications on Seasonal Malaria Chemoprevention. Genes (Basel). 2019 Jul 16;10(7).

431 2. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, et al.
432 Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to
433 Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8.

434 3. Ngum NH, Fakeh NB, Lem AE, Mahamat O. Prevalence of malaria and associated
435 clinical manifestations and myeloperoxidase amongst populations living in different altitudes of
436 Mezam division, North West Region, Cameroon. Malar J. 2023 Jan 19;22(1):20.

437 4. Gautret P, Legros F, Koulmann P, Rodier M, Jacquemin J-L. Imported Plasmodium
438 vivax malaria in France: geographical origin and report of an atypical case acquired in Central or
439 Western Africa. Acta tropica. 2001;78(2):177-81.

440 5. Mangoni ED, Severini C, Menegon M, Romi R, Ruggiero G, Majori G. Case report: An
441 unusual late relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and
442 Hygiene. 2003;68(2):159-60.

443 6. Russo G, Faggioni G, Paganotti GM, Djeunang Dongho GB, Pomponi A, De Santis R, et
444 al. Molecular evidence of Plasmodium vivax infection in Duffy negative symptomatic
445 individuals from Dschang, West Cameroon. Malar J. 2017 Feb 14;16(1):74.

446 7. Djeunang Dongho GB, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M,
447 Efeutmecheh Sangong R, et al. Plasmodium vivax Infections Detected in a Large Number of
448 Febrile Duffy-Negative Africans in Dschang, Cameroon. Am J Trop Med Hyg. 2021 Jan
449 12;104(3):987-92.

450 8. Ntumngia FB, McHenry AM, Barnwell JW, Cole-Tobian J, King CL, Adams JH. Genetic
451 variation among Plasmodium vivax isolates adapted to non-human primates and the implication
452 for vaccine development. Am J Trop Med Hyg. 2009 Feb;80(2):218-27.
453 9. Seraphin EH, Lagarde BJ, Richard P, Jules N, Farrick NO. Diversity, structure and health
454 of a cocoa based agroforest system in the Humid dense forest, East Cameroon. International
455 Journal of Biodiversity andConservation. 2021:165.
456 10. Akenji T, Ntonifor N, Kimbi H, Abongwa E, Ching J, Anong D, et al. The epidemiology
457 of malaria in Bolifamba, a rural setting of Mount Cameroon: Seasonal variations in
458 parasitological indices of transmission [MIM-TA-141660]. ACTA TROPICA; 2005:
459 ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS; 2005. p.
460 S295-S6.
461 11. Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. Molecular
462 typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of
463 Cameroon. Malar J. 2014 May 3;13:170.
464 12. Miguel RB, Coura JR, Samudio F, Suárez-Mutis MC. Evaluation of three different DNA
465 extraction methods from blood samples collected in dried filter paper in Plasmodium subpatent
466 infections from the Amazon region in Brazil. Rev Inst Med Trop Sao Paulo. 2013;55(3).
467 13. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular
468 epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive
469 and Duffy-negative populations in Ethiopia. Malar J. 2015 Feb 19;14:84.
470 14. Abagero BR, Rama R, Obeid A, Tolossa T, Legese F, Lo E, et al. Detection of Duffy
471 Blood Group Genotypes and Submicroscopic Plasmodium Infections Using Molecular
472 Diagnostic Assays in Febrile Malaria Patients. Res Sq. 2023 Dec 6.

473 15. Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of
474 Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad
475 Sci U S A. 2016 May 31;113(22):6271-6.
476 16. Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting
477 epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals
478 across Africa. International Journal of Infectious Diseases. 2021;108:63-71.
479 17. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.
480 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people.
481 Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5967-71.
482 18. Ketema T, Bacha K, Getahun K, Portillo HAD, Bassat Q. Plasmodium vivax
483 epidemiology in Ethiopia 2000-2020: A systematic review and meta-analysis. PLoS Negl Trop
484 Dis. 2021 Sep;15(9):e0009781.
485 19. Shanks GD, Hay SI, Omumbo JA, Snow RW. Malaria in Kenya's western highlands.
486 Emerg Infect Dis. 2005 Sep;11(9):1425-32.
487 20. Benavente ED, Manko E, Phelan J, Campos M, Nolder D, Fernandez D, et al. Distinctive
488 genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa.
489 Nat Commun. 2021 May 26;12(1):3160.
490 21. Siraj AS, Santos-Vega M, Bouma MJ, Yadeta D, Ruiz Carrascal D, Pascual M.
491 Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science. 2014
492 Mar 7;343(6175):1154-8.
493 22. Wamae K, Wambua J, Nyangweso G, Mwambingu G, Osier F, Ndung'u F, et al.
494 Transmission and Age Impact the Risk of Developing Febrile Malaria in Children with
495 Asymptomatic Plasmodium falciparum Parasitemia. J Infect Dis. 2019 Feb 23;219(6):936-44.

496 23. Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.
497 Comparison of Plasmodium Vivax Infections in Duffy Negatives From Community and Health
498 Center Collections in Ethiopia. Res Sq. 2023 Oct 3.
499 24. Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.
500 Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and
501 health centre collections in Ethiopia. Malar J. 2024 Mar 14;23(1):76.
502 25. Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine
503 candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a
504 Phase I trial. NPJ Vaccines. 2018;3:48.
505 26. Deo DA, Herningtyas EH, Intansari US, Perdana TM, Murhandarwati EH, Soesatyo M.
506 Difference between Microscopic and PCR Examination Result for Malaria Diagnosis and
507 Treatment Evaluation in Sumba Barat Daya, Indonesia. Trop Med Infect Dis. 2022 Jul 29;7(8).
508 27. Tapaopong P, da Silva G, Chainarin S, Suansomjit C, Manopwisedjaroen K, Cui L, et al.
509 Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and
510 Merozoite Surface Protein-1 in northwestern Thailand. Infect Genet Evol. 2023 Sep;113:105467.
511 28. Kepple D, Hubbard A, Ali MM, Abargero BR, Lopez K, Pestana K, et al. Plasmodium
512 vivax From Duffy-Negative and Duffy-Positive Individuals Share Similar Gene Pools in East
513 Africa. J Infect Dis. 2021 Oct 28;224(8):1422-31.
514 29. Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, et al. Local
515 adaptation and vector-mediated population structure in Plasmodium vivax malaria. Mol Biol
516 Evol. 2008 Jun;25(6):1245-52.
517 30. Feufack-Donfack LB, Sarah-Matio EM, Abate LM, Bouopda Tuedom AG, Ngano
518 Bayibéki A, Maffo Ngou C, et al. Epidemiological and entomological studies of malaria

519 transmission in Tibati, Adamawa region of Cameroon 6 years following the introduction of long-
520 lasting insecticide nets. Parasit Vectors. 2021 May 8;14(1):247.
521 31. Ossè RA, Tokponnon F, Padonou GG, Glitho ME, Sidick A, Fassinou A, et al. Evidence
522 of Transmission of Plasmodium vivax 210 and Plasmodium vivax 247 by Anopheles gambiae
523 and An. coluzzii, Major Malaria Vectors in Benin/West Africa. Insects. 2023 Feb 25;14(3).
524 32. Massebo F, Balkew M, Gebre-Michael T, Lindtjørn B. Entomologic inoculation rates of
525 Anopheles arabiensis in southwestern Ethiopia. Am J Trop Med Hyg. 2013 Sep;89(3):466-73.
526 33. Eligo N, Wegayehu T, Pareyn M, Tamiru G, Lindtjørn B, Massebo F. Anopheles
527 arabiensis continues to be the primary vector of Plasmodium falciparum after decades of malaria
528 control in southwestern Ethiopia. Malar J. 2024 Jan 9;23(1):14.
529 34. Ogola EO, Odero JO, Mwangangi JM, Masiga DK, Tchouassi DP. Population genetics of
530 Anopheles funestus, the African malaria vector, Kenya. Parasit Vectors. 2019 Jan 8;12(1):15.
531 35. Loy DE, Plenderleith LJ, Sundararaman SA, Liu W, Gruszczyk J, Chen YJ, et al.
532 Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related
533 ape parasites. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8450-e9.
534 36. Abebe A, Dieng CC, Dugassa S, Abera D, Shenkutie TT, Assefa A, et al. Genetic
535 differentiation of Plasmodium vivax duffy binding protein in Ethiopia and comparison with other
536 geographical isolates. Malar J. 2024 Feb 23;23(1):55.
537 37. Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in
538 Africa. Curr Biol. 2010 Feb 23;20(4):R166-73.
539 38. Campbell MC, Hirbo JB, Townsend JP, Tishkoff SA. The peopling of the African
540 continent and the diaspora into the new world. Curr Opin Genet Dev. 2014 Dec;29:120-32.
541


Mono-P. vivax
Mono-P. falciparum
Mixed P. vivax + P. falciparum
Negative
Latitude
Longitude
12
10
8
6
4
9
10
11
12
13
14
15
16
Bamenda
n=498
11%
13%
11%
65%
Bertoua
n=467
4%
44%
7%
45%
Buea
n=398
n=113
13%
20%
9%
58%
n=285
11%
43%
17%
29%
(C) OpenStreetMap contributors (C) CARTO

Figure 1.


(A)
Number of cases
0
20
40
60
80
100
Hospital
Community
Pv
Pv and Pf
(B)
Log parasitemia of P. vivax by qPCR
0
2
4
6
8
10
12
14
Pv
Pv and Pf

Figure 2.



Figure 3.


(A)
Frequency
80
60
40
20
0
E225K
K234E
K326E*
G339D**
N372K**
I379L*
G417V
W442C
(B)
PvDBP1 Mutations in Global P. vivax Isolates
Country
Thailand
Sudan
Ethiopia
China
Cameroon
Brazil
Botswana
R306S
K326E
L333F
G339D
K371E
N372K
N375D
I379L
D384G
E385K
K386N,Q
R390H
S398T
T404R
N417K
L424I
W437R
W442C
Mutation

Figure 4.


(A)
South America
Asia
Central-South Africa
East Africa
(B)
Central-South Africa
Cameroon
Botswana
East Africa
Uganda
Ethiopia
Sudan
Reference

Figure 5.